These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11948033)

  • 1. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.
    Rossi A; Kristufek P; Levine BE; Thomson MH; Till D; Kottakis J; Della Cioppa G;
    Chest; 2002 Apr; 121(4):1058-69. PubMed ID: 11948033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formoterol: a review of its use in chronic obstructive pulmonary disease.
    Cheer SM; Scott LJ
    Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
    Bauwens O; Ninane V; Van de Maele B; Firth R; Dong F; Owen R; Higgins M
    Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.
    D'Urzo AD; De Salvo MC; Ramirez-Rivera A; Almeida J; Sichletidis L; Rapatz G; Kottakis J;
    Chest; 2001 May; 119(5):1347-56. PubMed ID: 11348938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
    Dahl R; Greefhorst LA; Nowak D; Nonikov V; Byrne AM; Thomson MH; Till D; Della Cioppa G;
    Am J Respir Crit Care Med; 2001 Sep; 164(5):778-84. PubMed ID: 11549532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.
    Whale CI; Sovani MP; Mortimer KJ; Harrison TW; Tattersfield AE
    Br J Clin Pharmacol; 2008 Jun; 65(6):841-7. PubMed ID: 18394012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
    Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol.
    Steffensen I; Faurschou P; Riska H; Rostrup J; Wegener T
    Allergy; 1995 Aug; 50(8):657-63. PubMed ID: 7503401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD.
    La Piana GE; Corda L; Bertella E; Montemurro LT; Pini L; Tantucci C
    Int J Chron Obstruct Pulmon Dis; 2011; 6():399-405. PubMed ID: 21857779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
    Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
    Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study results.
    Bogdan MA; Aizawa H; Fukuchi Y; Mishima M; Nishimura M; Ichinose M
    BMC Pulm Med; 2011 Nov; 11():51. PubMed ID: 22085439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
    Hogan TJ; Geddes R; Gonzalez ER
    Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
    Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.